ALs MG / myasthenia gravis ( spierziekte ) werkt kan het ingezet worden voor o.a. MS . Wat denk je dat er dan gaat gebeuren met de koers .
ARGX-113
ARGX-113 is a first-in-class antibody fragment designed for the treatment of patients with severe autoimmune diseases associated with high levels of pathogenic immunoglobulin G, or IgG, antibodies for which few innovative biologic treatments have been approved and severe unmet medical need exists. ARGX-113 has been created to degrade circulating disease-causing autoimmune antibodies and has potential in many large and orphan indications: multiple sclerosis, immune thrombocytopenia, systemic lupus erythematosus, myasthenia gravis and skin blistering diseases.
CLINICAL TRIALS
Phase 2 clinical trial in MG and ITP; recruitment is ongoing.
Phase 1 safety trial in healthy volunteers completed.
Data set from Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) studies showed favorable safety profile and specific IgG reduction of up to 85 % with a long duration of effect, with repeated dosing of the drug.
MODE OF ACTION
ARGX-113 binds FcRn, blocks IgG recycling (including disease causing autoantibodies) and increases IgG clearance: resulting in faster remission and drastically reduced length and seriousness of acute autoimmune crisis
Antibody fragment designed using ABDEG™ technology
Nat Biotechnol 2005, Vacaro et al.
TARGET
Neonatal Fc receptor (FcRn):
Recycling receptor for IgG’s
Ability to rescue IgG from destruction
Responsible for maintenance of high concentration of IgG (including autoantibodies) in circulation
-----------------
Overigens kan ook de deal met Abbvie een hele grote worden ARGNX 115 cancer immunotherapie .
De pipeline is gewoon mooi verdeeld met zeer grote kaskrakers in het verschiet .
Tim (directeur ) blaakt van zelfvertrouwen
Laat er nu eerst maar een hele mooie deal komen voor ARGNx 111
ARGX-111 is a best-in-class SIMPLE Antibody™ with therapeutic potential for cancer metastases, targeting many cancer types such as gastric, renal, liver and brain.In Phase 1 clinical trials, ARGX-111 has demonstrated a very promising safety profile and initial signs of metabolic activity in patients with a specific genetic aberration (MET-amplification). Our current clinical development plan focuses on MET-amplified cancers